Clinical trials: MMR Vaccine
Measles, Mumps
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
This study will evaluate the immunogenicity and safety of Beijing Tiantan's MMR vaccine in subjects 18 months of age and older. The MMR vaccine may be administered as a second dose to 4-6 year-old persons with one dose…
- Conditions
- Measles, Mumps, Rubella, Adverse Event Following Immunisation
- Trial name
- NCT03160820
- Testing
- Measles, mumps and rubella Combined Vaccine, Live
- Where
- 4 sites in China
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Vaccination, Health Systems
Implementation and Evaluation of Tailored Interventions to Increase MMR and/or HPV Vaccine
The goal of the study is to monitor and evaluate the implementation of interventions that aim to increase HPV \& MMR vaccines among underserved communities across four European countries: Greece, Netherlands, Poland, and…
- Conditions
- Vaccination, Health Systems, Knowledge, Attitudes, Practice
- Trial name
- RIVER-EU (NCT06361628)
- Testing
- multicomponent intervention on vaccination awareness
- Where
- 4 sites in Greece, Netherlands and 2 more
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Measles, Mumps
ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)
This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00975507
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Varivax, Comparator: M-M-R II
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles
MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.
Healthy children who received two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated measles-mumps-rubella vaccine (MMR) or measles-mumps-rubella-varicella vaccine (MMRV) in their second year of life.The purpose of this…
- Trial name
- NCT02712203
- Testing
- MMR vaccine / MMRV vaccine
- Volunteers
- 5,808 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Measles, Mumps
Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines
The purpose of this study is to see if the MMR and chickenpox vaccines work as well in premature infants as in children that were carried to full term.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00138255
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
High Risk for HIV
Zambia SiVET MMR Tdap-IPV
Participants will receive vaccination for measles, mumps, and rubella (MMR) and tetanus, diphtheria, pertussis, and inactivated polio (Tdap-IPV).
- Trial name
- SiVET (NCT02589678)
- Testing
- Tdap - IPV Vaccine, MMR Vaccine
- Where
- 2 sites in Zambia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Emory University
Vaccine Response Impaired
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
This study evaluates seroconversion against measles, mumps, rubella and yellow fever following vaccination. One-third of children will receive both yellow fever and measles, mumps, and rubella (MMR) vaccines on the same day; one…
- Trial name
- NCT03368495
- Testing
- Co-administration of MMR/YF, MMR followed by YF, YF followed by MMR
- Where
- 4 sites in Argentina
- Volunteers
- 851 people, healthy volunteers welcome
- Sponsor
- Alba Maria Ropero
Tetanus, Acellular Pertussis
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years
The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and (measles mumps rubella) MMR vaccines, compared…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00871117
- Testing
- GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
- Where
- 11 sites in United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Poliomyelitis
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children
The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM Polio to that of Sanofi Pasteur MSD's RepevaxTM, when co-administered with a second dose of PriorixTM, in healthy 3 and…
- Conditions
- Acellular Pertussis, Poliomyelitis, Tetanus, Diphtheria
- Trial name
- NCT01245049
- Testing
- Boostrix PolioTM, RepevaxTM, PriorixTM
- Where
- 13 sites in United Kingdom
- Volunteers
- 387 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
As measles-mumps-rubella (MMR) vaccination is established as routine childhood practice in most industrialised countries and varicella vaccination is now being introduced in many countries during the second year of life, a…
- Conditions
- Varicella, Rubella, Measles, Mumps
- Trial name
- NCT00353288
- Testing
- MeMuRu-OKA (study vacc), MMR, Varicella vacc (control)
- Where
- 39 sites in France, Germany and 1 more
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sepsis Syndrome
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers…
- Trial name
- NCT04475081
- Testing
- MMR vaccine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Immune Responses to Two Dose Varivax +/- MMR-II
This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without ProQuad, another measles, mumps, rubella, and…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00258726
- Testing
- MMR-II, Pro-Quad, Varivax
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rubella, Measles
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \&…
- Conditions
- Rubella, Measles, Mumps
- Trial name
- NCT01702428
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 90 sites in United States, Estonia and 4 more
- Volunteers
- 5,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rubella, Mumps
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in the US.
- Conditions
- Rubella, Mumps, Measles
- Trial name
- NCT02058563
- Testing
- Priorix®, Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
- Where
- 17 sites in United States, Estonia and 1 more
- Volunteers
- 996 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Making Decisions About the Measles-Mumps-Rubella Vaccine
The goal of this study is to determine whether a computer-based intervention that delivers individually-tailored educational messages about the MMR vaccine increases MMR vaccine-hesitant parents' intentions to have their children…
- Conditions
- Measles, Mumps, Rubella, MMR Vaccination
- Trial name
- NCT01369394
- Testing
- Behavioral: Computer-based tailoring system
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Immunotoxicity, Vaccine
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.
- Trial name
- NCT05161845
- Testing
- Measles, Mumps and Rubella Combined Vaccine, Live
- Where
- China
- Volunteers
- 1,068 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Measles, Mumps
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on…
- Conditions
- Measles, Mumps, Rubella, Hepatitis A
- Trial name
- NCT00313950
- Testing
- Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company